PTCD3

Across TCGA pan-cancer cohorts, PTCD3 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated PTCD3 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), where higher PTCD3 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PTCD3 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

CESC, UCEC, and STAD are the cancer types where PTCD3 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CESC	DFS	Median	II,III,IV	0.053	0.786	<.001	30	view →
UCEC	DFS	Median	All	0.971	0.616	.005	10	view →
STAD	OS	Median	III,IV	0.500	0.633	.010	5	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

PTCD3–CESC (DFS)

Open the CESC breakdown →